Athersys, Inc. (NASDAQ:ATHX) shares were up 4.8% on Thursday . The company traded as high as $2.63 and last traded at $2.28. Approximately 823,150 shares were traded during trading, a decline of 24% from the average daily volume of 1,089,710 shares. The stock had previously closed at $2.39.
A number of research analysts recently weighed in on ATHX shares. Zacks Investment Research raised Athersys from a “hold” rating to a “buy” rating and set a $2.50 price target on the stock in a research note on Monday, September 18th. Maxim Group set a $12.00 price objective on Athersys and gave the stock a “buy” rating in a research note on Monday, August 7th. Finally, ValuEngine raised Athersys from a “sell” rating to a “hold” rating in a research note on Friday, September 15th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $7.17.
The company’s market capitalization is $254.02 million. The company has a 50 day moving average of $2.12 and a 200 day moving average of $1.68.
Athersys (NASDAQ:ATHX) last issued its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.06) EPS for the quarter, hitting analysts’ consensus estimates of ($0.06). Athersys had a negative return on equity of 121.47% and a negative net margin of 729.07%. The firm had revenue of $0.67 million for the quarter, compared to analysts’ expectations of $0.96 million. During the same period in the previous year, the firm posted ($0.08) EPS. The business’s revenue for the quarter was up 12.4% compared to the same quarter last year. On average, analysts predict that Athersys, Inc. will post ($0.24) EPS for the current year.
In other news, EVP John J. Harrington sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, September 18th. The stock was sold at an average price of $2.17, for a total value of $32,550.00. Following the sale, the executive vice president now directly owns 679,416 shares of the company’s stock, valued at approximately $1,474,332.72. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 9.40% of the company’s stock.
Several institutional investors and hedge funds have recently modified their holdings of ATHX. Bank of America Corp DE boosted its position in shares of Athersys by 17.2% in the 1st quarter. Bank of America Corp DE now owns 61,580 shares of the biopharmaceutical company’s stock worth $105,000 after purchasing an additional 9,019 shares in the last quarter. Wells Fargo & Company MN boosted its position in shares of Athersys by 4.8% in the 1st quarter. Wells Fargo & Company MN now owns 61,176 shares of the biopharmaceutical company’s stock worth $105,000 after purchasing an additional 2,800 shares in the last quarter. SG Americas Securities LLC boosted its position in shares of Athersys by 329.7% in the 2nd quarter. SG Americas Securities LLC now owns 73,434 shares of the biopharmaceutical company’s stock worth $111,000 after purchasing an additional 56,345 shares in the last quarter. State of Wisconsin Investment Board bought a new stake in shares of Athersys in the 2nd quarter worth approximately $113,000. Finally, Blair William & Co. IL boosted its position in shares of Athersys by 708.0% in the 2nd quarter. Blair William & Co. IL now owns 80,804 shares of the biopharmaceutical company’s stock worth $122,000 after purchasing an additional 70,804 shares in the last quarter. 19.08% of the stock is currently owned by hedge funds and other institutional investors.
Athersys, Inc is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company’s MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients.
Receive News & Ratings for Athersys Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys Inc. and related companies with MarketBeat.com's FREE daily email newsletter.